Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment.
Li J, Huang T, Hua J, Wang Q, Su Y, Chen P, Bidlingmaier S, Li A, Xie Z, Bidkar AP, Shen S, Shi W, Seo Y, Flavell RR, Gioeli D, Dreicer R, Li H, Liu B, He J. Li J, et al. Among authors: dreicer r. J Exp Clin Cancer Res. 2023 Mar 11;42(1):61. doi: 10.1186/s13046-023-02636-x. J Exp Clin Cancer Res. 2023. PMID: 36906664 Free PMC article.
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R. McNeel DG, et al. Among authors: dreicer r. Cancer Immunol Res. 2014 Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4. Cancer Immunol Res. 2014. PMID: 25189164 Free PMC article. Clinical Trial.
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. Wang S, et al. Among authors: dreicer r. Clin Cancer Res. 2021 Mar 1;27(5):1305-1315. doi: 10.1158/1078-0432.CCR-20-3310. Epub 2020 Dec 8. Clin Cancer Res. 2021. PMID: 33293372 Free PMC article.
Highlights in Genitourinary (Prostate) Cancer.
Dreicer R. Dreicer R. JAMA Oncol. 2016 Oct 1;2(10):1257-1258. doi: 10.1001/jamaoncol.2016.3325. JAMA Oncol. 2016. PMID: 27541619 No abstract available.
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Stein CA, Levin R, Given R, Higano CS, Nemeth P, Bosch B, Chapas-Reed J, Dreicer R. Stein CA, et al. Among authors: dreicer r. Urol Oncol. 2018 Feb;36(2):81.e9-81.e16. doi: 10.1016/j.urolonc.2017.10.018. Epub 2017 Nov 14. Urol Oncol. 2018. PMID: 29150328 Free article. Clinical Trial.
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Barata P, Cooney M, Tyler A, Wright J, Dreicer R, Garcia JA. Barata P, et al. Among authors: dreicer r. Invest New Drugs. 2018 Jun;36(3):451-457. doi: 10.1007/s10637-018-0574-0. Epub 2018 Feb 23. Invest New Drugs. 2018. PMID: 29476383 Clinical Trial.
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI. Autio KA, et al. Among authors: dreicer r. JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168. JAMA Oncol. 2018. PMID: 29978216 Free PMC article. Clinical Trial.
257 results